OX
OXB.LSE Oxford BioMedica PLC
- Market cap
- GBX 662M
- P/E
- -
- P/B
- 11.09x
- ROE
- -254.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is OXB.LSE undervalued?
Graham numberThe Graham number of Oxford BioMedica PLC cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Oxford BioMedica PLC fundamental analysis
No fundamental analysis for Oxford BioMedica PLC yet.
Oxford BioMedica PLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Oxford BioMedica PLC
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems; InAAVate, a proprietary "plug and play' dual-plasmid system for transient transfection, as well as a standard triple transfection system for AA…
Full company profileOxford BioMedica PLC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Oxford BioMedica PLC annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 27.8M | 37.6M | 66.8M | 64.1M | 87.7M | 143M | 140M | 89.5M | 129M | 169M | 319M |
| Gross Profit | 15.9M | 19.1M | 44.0M | 28.3M | 46.1M | 82.6M | 69.2M | 39.7M | 53.0M | 66.0M | 115M |
| Operating Income | -11.3M | -5.67M | 8.00M | -12.6M | -5.69M | 20.8M | -30.2M | -184M | -39.4M | -29.6M | -88.6M |
| EBITDA | -11.7M | 2.03M | 12.3M | -9.60M | 4.14M | 33.2M | -10.9M | -149M | -15.0M | -9.12M | -42.3M |
| Net Income | -16.6M | -9.02M | 7.54M | -16.1M | -6.25M | 19.0M | -39.2M | -157M | -43.2M | -30.1M | -148M |
| EPS | -0.30 | -0.15 | 0.11 | -0.22 | -0.08 | 0.22 | -0.41 | -1.63 | -0.42 | -0.27 | -1.22 |
| Balance Sheet | |||||||||||
| Total Assets | 56.9M | 65.4M | 112M | 123M | 184M | 237M | 460M | 252M | 232M | 326M | 299M |
| Total Liabilities | 44.3M | 59.3M | 77.7M | 47.3M | 71.2M | 49.9M | 224M | 175M | 171M | 234M | 241M |
| Shareholders' Equity | 12.6M | 6.15M | 34.7M | 75.6M | 113M | 187M | 205M | 74.0M | 57.0M | 91.3M | 58.1M |
| Cash & Short-term Investments | 15.3M | 14.3M | 32.2M | 19.0M | 47.0M | 109M | 141M | 104M | 60.7M | 96.9M | 75.3M |
| Total Debt | 34.4M | 36.9M | 41.2M | 8.39M | 13.8M | 9.34M | 114M | 111M | 109M | 148M | 159M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -5.11M | 2.98M | 12.9M | -3.51M | 3.12M | 25.5M | -12.6M | -28.5M | -50.6M | -5.45M | -73.4M |
| Capital Expenditure | 6.46M | 1.97M | 10.1M | 25.8M | 13.4M | 9.46M | 16.3M | 9.83M | 7.50M | 4.76M | 27.6M |
| Free Cash Flow | -11.6M | 1.01M | 2.72M | -29.3M | -10.2M | 16.0M | -28.9M | -38.3M | -58.1M | -10.2M | -101M |
| Ratios | |||||||||||
| ROE | -131.9% | -146.7% | 21.7% | -21.2% | -5.5% | 10.1% | -19.1% | -212.8% | -75.7% | -33.0% | -254.5% |
| ROA | -29.2% | -13.8% | 6.7% | -13.1% | -3.4% | 8.0% | -8.5% | -62.4% | -18.6% | -9.2% | -49.5% |
| Net Profit Margin | -59.9% | -24.0% | 11.3% | -25.1% | -7.1% | 13.3% | -28.0% | -175.9% | -33.5% | -17.9% | -46.3% |
| Debt to Equity | 2.73x | 6.00x | 1.18x | 0.11x | 0.12x | 0.05x | 0.56x | 1.51x | 1.91x | 1.62x | 2.73x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Oxford BioMedica PLC dividends
Oxford BioMedica PLC has not paid dividends in the last 9 fiscal years.
Last stock split: 1:50 on May 30, 2018.
Who owns Oxford BioMedica PLC
- Insiders 20.50%
- Institutions 65.19%
- Public & others 14.31%
- Shares outstanding 121M
- Free float 60.8M
Oxford BioMedica PLC company profile
- Company name
- Oxford BioMedica PLC
- Ticker
- OXB.LSE
- ISIN
- GB00BDFBVT43
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,017
- Fiscal year end
- December
- Address
- Windrush Court, Oxford, United Kingdom, OX4 6LT
- Phone
- 44 1865 783 000
- Website
- oxb.com
About Oxford BioMedica PLC
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems; InAAVate, a proprietary "plug and play' dual-plasmid system for transient transfection, as well as a standard triple transfection system for AAV-based gene therapies. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.
Oxford BioMedica PLC management
10- Dr. Frank MathiasCEO & Director · born 1962
- Dr. Lucinda Clair Crabtree Ph.D.CFO & Director · born 1979
- Mr. Eric SchmidhäuserChief Operating Officer
- Ms. Sophia BolhassanHead of Investor Relations
- Ms. Natalie Louise WalterChief Legal Officer & Company Secretary · born 1973
- Ms. Lisa DomanChief People Officer
- Dr. Kyriacos Mitrophanous Ph.D.Chief Innovation Officer
- Ms. Kati HudsonHead of Intellectual Property & Contracts
- Mr. David M. Backer M.B.A.Durham Site Head
- Dr. Sebastien RibaultChief Business Officer